Inactive Instrument

Zyla Life Sciences

Equities

Biotechnology & Medical Research

Egalet Corporation Reports Earnings Results for the Full Year Ended December 31, 2018

March 29, 2019 at 04:38 pm EDT

Egalet Corporation announced earnings results for the full year ended December 31, 2018. For the full year, the company announced total revenue was USD 30.353 million compared to USD 26.136 million a year ago. Operating loss was USD 57.589 million compared to USD 68.200 million a year ago. Net loss was USD 95.454 million compared to USD 69.359 million a year ago. Basic loss per share was USD 1.81 compared to USD 2.05 a year ago.

Latest news about Zyla Life Sciences

Zyla Life Sciences Repaid All Outstanding Indebtedness and Terminated the Commitment Under its Revolving Credit Agreement	20-05-20	CI
Assertio and Zyla Life Sciences Announces Board Appointments to Combined Company	20-05-20	CI
Assertio Therapeutics, Inc. completed the acquisition of Zyla Life Sciences.	20-05-19	CI
Transcript : Zyla Life Sciences - Shareholder/Analyst Call	20-05-19
Transcript : Zyla Life Sciences, Q1 2020 Earnings Call, May 15, 2020	20-05-15
Zyla Life Sciences Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-14	CI
Transcript : Zyla Life Sciences, 2019 Earnings Call, Mar 27, 2020	20-03-27
Zyla Life Sciences Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-26	CI
Zyla Life Sciences Auditor Raises 'Going Concern' Doubt	20-03-25	CI
Zyla Life Sciences and Assertio Therapeutics Announce Management Appointments	20-03-17	CI
Assertio Therapeutics, Inc. entered into an agreement to acquire Zyla Life Sciences for $20.9 million.	20-03-15	CI
Transcript : Zyla Life Sciences - Shareholder/Analyst Call	19-12-17
Transcript : Zyla Life Sciences, Q3 2019 Earnings Call, Nov 14, 2019	19-11-14
Zyla Life Sciences Announces Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2019	19-11-13	CI
Zyla Life Sciences Announces Executive Changes	19-10-23	CI
Transcript : Zyla Life Sciences, Q2 2019 Earnings Call, Aug 13, 2019	19-08-13
Zyla Life Sciences Announces Management Changes	19-08-13	CI
Zyla Life Sciences Provides Sales Guidance for the Year 2019	19-08-13	CI
Zyla Life Sciences Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI
Zyla Life Sciences Announces Board Changes	19-06-19	CI
Zyla Life Sciences Appoints H. Jeffrey Wilkins, M.D. as Senior Vice President and Chief Medical Officer	19-06-12	CI
Zyla Life Sciences Announces Board Changes	19-06-06	CI
Egalet Corporation has Changed its Name to Zyla Life Sciences	19-06-03	CI
Transcript : Egalet Corporation, Q1 2019 Earnings Call, May 16, 2019	19-05-16
Patrick Shea, Senior Vice President and Chief Commercial Officer, Will Be Leaving Egalet Corporation, Effective June 8, 2019	19-05-16	CI

Chart Zyla Life Sciences

Duration

Period

More charts

Company Profile

Zyla Life Sciences, formerly Egalet Corporation, is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. Its product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+64.68%	62.59B
IQVIA HOLDINGS INC.	-2.01%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.77%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.89%	19.09B
BIO-TECHNE CORPORATION	+3.69%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.96%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research